Results 241 to 250 of about 105,256 (293)

3-Nitrotyrosine activates excitatory interneurons by inhibiting GABA receptors in the rat spinal dorsal horn. [PDF]

Pain Rep
Kaimochi Y, Yamanaka M, Taniguchi W, Nishio N, Matsuyama Y, Ueno T, Miyake R, Yamamoto Y, Nakatsuka T, Yamada H.   +9 more
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Advances in pulmonary neuroendocrine cells and their cellular interactions in asthma pathogenesis. [PDF]

Front Pharmacol
Wang L, Wang H, Yuan Y, Ye W, Fang X.
europepmc   +1 more source

Sex‐specific impact of repeated adolescent vapour exposure to JWH‐018 on dopamine response, behaviour and pharmacokinetics across adolescence and adulthood

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Alarming trends show that vaping e‐cigarettes containing synthetic cannabinoid receptor agonists, such as JWH‐018, is increasing among youth. However, the effects of these trends are unclear in both sexes. We therefore characterized the neuropharmacological effects of adolescent JWH‐018 inhalation in male and female rats.
Nicholas Pintori, Cristina Manis, Enrica Spano, Nicola Simola, Alessandro Ieraci, Pierluigi Caboni, Gaetano Di Chiara, Maria Antonietta De Luca   +7 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Computational drug repositioning approach to predict multi-target therapeutics for epilepsy. [PDF]

Sci Rep
Kumar P, Kumar V, Chauhan R, Saini V, Kumar A.   +4 more
europepmc   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Targeting γ-aminobutyric acid pathways in irritable bowel syndrome: bridging central nervous system, enteric dysfunction, and the microbiota-gut-brain axis. [PDF]

Front Pharmacol
Lambiase C, Rettura F, Sciumè GD, Tedeschi R, Grosso A, Cancelli L, Bottari A, Fornai M, Antonioli L, de Bortoli N, Bellini M.   +10 more
europepmc   +1 more source

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source

A PK/PD study on antihyperalgesia by an α2/3‐GABAA receptor PAM in mice: Lack of tolerance liability and potential involvement of γ1‐GABAA receptors

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose GABAA receptors (GABAARs) are heteropentameric ion channels that control almost all CNS functions, including spinal nociception. Most GABAARs contain a γ2 subunit but differ in their α and β subunit composition. TPA023B is an α2/α3 subtype selective, non‐sedative, positive allosteric modulator (PAM) with antihyperalgesic
Elena Neumann, Mariana O. Popa, Karen T. Elvers, Misa Oyama, Daniel Ulrich, Marcus Hanley, Gui Jie Feng, Thomas Hathaway, William T. Ralvenius, Thomas Grampp, Dietmar Benke, John R. Atack, Hanns Ulrich Zeilhofer   +12 more
wiley   +1 more source